GenScript, a global biotech, has signed a partnership agreement for the manufacture of GMP plasmids with Genopis, a company that specializes in plasmid DNA-based technology and provides contract development and manufacturing organization (CDMO) services. By entering this strategic partnership agreement, GenScript and Genopis establish a revenue-sharing agreement for the promotion, selling, and production of GMP plasmids globally.
 
“We are glad to collaborate with Genopis. Last month, our plasmid and virus facility in Zhenjiang was put into operation. It is a milestone on the path to industrialization of the gene and cell therapy products, pioneered by GenScript, and we have been the leading company in China in this field,” said Brian Min, chief executive officer, biologics development business unit, GenScript. “Genopis is a U.S. cGMP accredited manufacturer with the capability to produce GMP plasmid, and this partnership will further expand our services to the globe. We will leverage the strengths from both companies. Genopis’ experience in and ability to efficiently execute GMP production for both clinical studies and commercial purposes are key strengths for this cooperation, which finally will accelerate the development of the new and novel drugs and therapies.”
 
Paul Kim, chief strategic officer, Genopis, said, “We are excited about this collaboration. We are a unique company, not only in the U.S., but globally when it comes to plasmid DNA production. We actually began cultivating this field many years ago, and we have the extensive experience and powerful teams. GenScript have done a lot in promoting the industrialization of gene and cell therapy products in China, and have the great reputation globally. The partnership will not only help customers effectively diversify risks, but also lower costs and shorten the production cycle, and maximize customer resources to better use in the early R&D phase.”